Sarcomas are neoplastic malignancies that typically arise in tissues of mesenchymal origin. The identification of novel molecular mechanisms leading to sarcoma formation and the establishment of new therapies has been hampered by several critical factors. Human uterine leiomyosarcoma (Ut-LMS) develops more frequently in the muscle tissue layer of the uterine body than in the uterine cervix. Although the development of gynecologic tumors is often correlated with the secretion of female hormones; that of human Ut-LMS does not and its risk factors remain unknown. Importantly, a diagnostic biomarker that can distinguish malignant Ut-LMS from benign tumor uterine leiomyoma (LMA) has yet to be established. Therefore the risk factor(s) associated with human Ut-LMS to establish a diagnosis and novel therapeutic method. Proteasome b-ring subunit LMP2/b1i-deficient mice spontaneously develop Ut-LMS, with a disease prevalence of ~40% by 14 months of age. We shown that LMP2/b1i expression was absent in human Ut-LMS, but present in other human uterine mesenchymal tumors including uterine LMA. Therefore, defective-LMP2/b1i expression may be one of the risk factors for human Ut-LMS. LMP2/b1i is a potential diagnostic biomarker for human Ut-LMS, and may be a targeted-molecule for a new therapeutic approach.
Although we has previously demonstrated that abnormal expression of the ovarian steroid receptors, Tp53, ki-67 and mutations in Tp53
were frequently associated with Ut-LMS, defective LMP2/ b1i expression appears to be more characteristic of human Ut-LMS than these factors. 15, 16 A female hormonal imbalance is often a risk factor for development of tumors in the case of gynecological cancers. 7 As in the case of uterine LMA, however, a correlation between the development of Ut-LMS, the female hormone, and hormone receptors has ( Table 1 , Table 2 ). Clarifying correlations between these factors and the development of human Ut-LMS and the identifying specific risk factors may lead to the development of new clinical treatments for the disease. Table 2 . LMP2 expression levels in human myometrium, uterine leiomyoma (Ordinaly leiomyoma, Cellular leiomyoma, Tumor of uncertain malignant potential), bizarre leiomyoma, uterine leiomyosarcoma. IHC experiments individually performed at several medical facilities revealed a serious loss in the ability to induce LMP2/b1i expression in human uterine leiomyosarcoma tissues compared to that in uterine leiomyoma or bizarre leiomyoma located in the same tissue section. Normal total: 59 cases, uterine leiomyoma total: 53 cases, Bizarre leiomyoma total: 3 cases, uterine leiomyosarcoma total: 59 cases. 
